



Ketanserin (101): sc-66079

BACKGROUND

Ketanserin is a selective serotonin receptor antagonist with the highest affinity for the serotonin 5-HT_{2A} receptor, though it also weakly binds to the 5-HT_{2C}, 5-HT_{2B}, 5-HT_{1D}, α -adrenergic, and dopamine receptors. Ketanserin is useful as a radioligand in receptor binding assays when it is radioactively labeled with tritium. Ketanserin has a molecular weight of 395.43 g/mol. Ketanserin improves of renal functions by significant increasing creatinine clearance and urine output. This molecule can be effective as a drug in lowering blood pressure in essential hypertension, as well as for inhibiting platelet aggregation, especially in older patients. Ketanserin may also be a useful non-dopaminergic target for therapies of some basal ganglia disorders such as Parkinson's disease.

REFERENCES

1. Naslund, T.C., Merrell, W.J., Nadeau, J.H. and Wood, A.J. 1988. α -adrenergic blockade makes minimal contribution to Ketanserin's hypotensive effect. *Clin. Pharmacol. Ther.* 44: 699-703.
2. Casagrande, P., Valvo, E., Bedogna, V., Loschiavo, C., Giorgetti, P., Graziani, M.S. and Maschio, G. 1990. Antihypertensive therapy with Ketanserin: effects on central and renal hemodynamics, and microalbuminuria. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 28: 79-83.
3. Petry, A., Wulf, H. and Baumgärtel, M. 1995. The influence of Ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation. *Anaesthesia* 50: 312-316.
4. Verbeke, M., Smöllich, B., van de Voorde, J., de Ridder, L. and Lameire, N. 1996. Beneficial influence of Ketanserin on autoregulation of blood flow in post-ischemic kidneys. *J. Am. Soc. Nephrol.* 7: 621-627.
5. Podoleanu, D. and Cotoi, S. 1996. Role of Ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease. *Rom. J. Intern. Med.* 34: 49-54.
6. Borawski, J., Rydzewski, A., Azzadin, A., Buczek, W. and Mysliwiec, M. 1998. Modulation of hematopoiesis by Ketanserin in erythropoietin-treated uremic patients: evidence from platelet studies. *Platelets* 9: 31-35.
7. Marazziti, D., Giannaccini, G., Giromella, A., Betti, L., Pesce, D., Nardi, I., Rossi, A., Lucacchini, A. and Cassano, G.B. 2003. ³H-Ketanserin binding sites in different psychiatric disorders. *Neurochem. Int.* 42: 511-516.
8. Xie, H.H., Shen, F.M., Cao, Y.B., Li, H.L. and Su, D.F. 2005. Effects of low-dose Ketanserin on blood pressure variability, baroreflex sensitivity and end-organ damage in spontaneously hypertensive rats. *Clin. Sci.* 108: 547-552.
9. Nowak, P., Szczerbak, G., Biedka, I., Drosik, M., Kostrzewa, R.M. and Brus, R. 2006. Effect of Ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. *In vivo microdialysis study.* *J. Physiol. Pharmacol.* 57: 583-597.

SOURCE

Ketanserin (101) is a mouse monoclonal antibody raised against Ketanserin.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 100 μ g IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Ketanserin (101) is recommended for detection of Ketanserin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.